iTeos Therapeutics, Inc. (ITOS)

0.20% (1D)

Market Cap	447.68M
Revenue (ttm)	35.00M
Net Income (ttm)	-130.81M
Shares Out	44.17M
EPS (ttm)	-3.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	862,954
Open	10.13
Previous Close	10.13
Day's Range	10.12 - 10.18
52-Week Range	4.80 - 18.13
Beta	1.49
Analysts	Hold
Price Target	10.60 (+4.59%)
Earnings Date	Aug 7, 2025

About ITOS

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company’s lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2020
• Employees: 173
• Stock Exchange: NASDAQ
• Ticker Symbol: ITOS
• Website: https://www.iteostherapeutics.com

Financial Performance

In 2024, iTeos Therapeutics's revenue was $35.00 million, an increase of 177.89% compared to the previous year's $12.60 million. Losses were -$134.41 million, 19.3% more than in 2023.

Analyst Summary

According to 6 analysts, the average rating for ITOS stock is "Hold." The 12-month stock price target is $10.6, which is an increase of 4.59% from the latest price.

Price Target

$10.6

(4.59% upside)

Analyst Consensus: Hold